Table 1.
Summary of significant lipoprotein differences between minocycline and placebo expressed as the % ratio of time-point 3/time-point 1, measured by the AXINON® lipoFIT® analysis platform. LVLDL-p: concentration of large VLDL particles; VLDL-s: mean diameter of VLDL particles; VLDL-c: cholesterol concentration in VLDL class; LDL.C-c: cholesterol concentration in LDL subclass small particles; Sig: significance (p value); Adj Sig: significance adjusted for multiple testing with Bonferroni.
| Metabolite | Minocycline (N = 11) | Placebo (N = 7) | Sig | Adj Sig | ||
|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | |||
| LVLDL-p | 137.77 | 45.75 | 60.37 | 52.58 | 0.0216 | 0.5391 |
| VLDL-s | 104.01 | 3.75 | 95.39 | 6.39 | 0.0031 | 0.0781 |
| VLDL-c | 104.32 | 10.66 | 90.76 | 14.61 | 0.0422 | 1.0555 |
| LDL.C-c | 118.75 | 17.41 | 80.45 | 12.67 | 0.0002 | 0.0043 |
| Triglycerides | 103.62 | 25.71 | 63.47 | 21.84 | 0.0043 | 0.1072 |